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Abstract 
 
Negative symptoms and neurocognitive performance have been reported to be negatively 
associated in patients with emerging psychosis. However, most previous studies focused on 
patients with frank psychosis and did not differentiate between subdomains of negative 
symptoms. Hence, we aimed to elucidate the specific relationship between negative 
symptoms and cognitive functioning in patients with an at-risk mental state (ARMS) for 
psychosis. Data from 154 ARMS patients collected within the prospective Früherkennung 
von Psychosen (FePsy) study were analysed. Negative symptoms were assessed with the 
Scale for the Assessment of Negative Symptoms (SANS) and cognitive functioning with an 
extensive neuropsychological test battery. Regression analyses revealed significant negative 
associations between negative symptoms and cognitive functioning, particularly in the 
domains of nonverbal intelligence and verbal fluency. When analyzing each negative 
symptom domain separately, alogia and asociality/anhedonia were significantly negatively 
associated with nonverbal intelligence and alogia additionally with verbal fluency. Overall, our 
results in ARMS patients are similar to those reported in patients with frank psychosis. The 
strong negative association between verbal fluency and negative symptoms may be 
indicative of an overlap between these constructs. Verbal fluency might have a strong 
influence on the clinical impression of negative symptoms (particularly alogia) and vice versa.  
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1. Introduction 
 
Early detection and intervention in patients with an at-risk mental state for psychosis (ARMS) 
represents a growing and promising field of research (Riecher-Rössler and McGorry, 2016; 
Riecher-Rössler and Studerus, 2017). ARMS patients are exposed to a high risk of 
developing frank psychosis, with transition risks up to 36% after 3 years of follow-up (Fusar-
Poli et al., 2012a). Previous studies showed that not only positive psychotic symptoms such 
as hallucinations, delusions and thought disorders, but also negative symptoms (Cotter et al., 
2014) and cognitive impairments (for meta-analysis see Hauser et al., 2017) are frequently 
present in ARMS patients. 
 Negative symptoms have previously been identified as a central clinical feature of 
psychosis (for review see Strauss and Cohen, 2017). Currently, the distinction of 5 negative 
symptom domains, namely blunted affect, alogia, asociality, avolition and anhedonia has 
become widely accepted (Strauss and Cohen, 2017). Negative symptoms are already 
present in ARMS patients and patients with a first-episode psychosis (FEP) and several 
studies highlighted their importance regarding the outcome of these patient groups. More 
severe negative symptoms are related to poorer social and role functioning in ARMS (Carrión 
et al., 2016; Cotter et al., 2014) and FEP patients (Diaz-Caneja et al., 2015), and negative 
symptoms represent significant predictors for conversion to psychosis (Demjaha et al., 2012; 
Piskulic et al., 2012; Riecher-Rössler et al., 2009; Valmaggia et al., 2013).  
Apart from positive and negative symptoms, cognitive impairments are regarded as a 
core feature of psychosis and are present in a considerable number of ARMS and FEP 
patients (Hauser et al., 2017). Although less severe than in FEP patients, ARMS patients 
show significant and widespread impairments in different domains of cognitive functioning 
such as general intelligence, attention/vigilance, verbal learning, visual learning, social 
cognition, executive functioning, processing speed, verbal fluency, working memory and 
verbal and visual memory (Fusar-Poli et al., 2012b; Hauser et al., 2017). It has been shown 
that ARMS patients with later transition to psychosis perform significantly worse in cognitive 
tasks than patients without later transition in nearly all cognitive domains (Hauser et al., 
2017; Riecher-Rössler and Studerus, 2017; Studerus et al., 2016). In longitudinal studies, 
cognitive impairments at baseline predicted poor social, role and occupational outcome 
(Cotter et al., 2014).  
So far, many studies have focused on associations between negative symptoms and 
cognitive functioning in FEP patients and/or individuals with a lifetime history of psychosis 
(de Gracia Dominguez et al., 2009). A systematic review of 58 studies (5009 individuals) 
found that higher levels of negative symptoms were modestly associated with lower cognitive 
functioning (correlations from -.29 to -.12), with the highest correlation between negative 
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symptoms and verbal fluency. In contrast, positive psychotic symptoms were not significantly 
associated with cognition (de Gracia Dominguez et al., 2009). So far, only few studies have 
investigated the association between negative symptoms and cognitive functioning in ARMS 
patients and those that exist have found similar results as in FEP patients. Specifically, 
higher levels of negative symptoms were associated with slower processing speed and 
poorer performance on verbal tasks involving verbal learning and memory or verbal fluency 
(Lindgren et al., 2010; Meyer et al., 2014), lower performance accuracy (Gur et al., 2015), 
poorer executive functioning, vigilance and problem solving (Meyer et al., 2014) and a 
general poorer performance in neurocognitive functioning (Gur et al., 2015; Meyer et al., 
2014). However, the majority of these studies included relatively small sample sizes or did 
not differentiate between the above mentioned five negative symptom domains. 
 Hence, the aim of this study was to evaluate the relationship between negative 
symptoms and cognitive functioning in ARMS patients, analyzing each negative symptom 
domain separately.  
 We hypothesized, that worse neurocognitive performance would be associated with a 
higher level of negative but not positive psychotic symptoms in ARMS patients. Based on the 
findings reported in FEP patients (de Gracia Dominguez et al., 2009), we expected to find the 
strongest associations between negative symptoms and verbal fluency tasks.  
 
2. Methods 
 
2.1 Setting and Recruitment 
The data analysed in this study were collected within the prospective Früherkennung von 
Psychosen (FePsy; early detection of psychosis) study, which aims to improve early 
detection of psychosis (Riecher-Rössler et al., 2007; Riecher-Rössler et al., 2009). Patients 
were recruited via the FePsy Clinic, University of Basel Psychiatric Hospital Basel, 
Switzerland, which was set up specifically to identify, assess, and treat individuals in the 
early stages of psychosis. All patients were recruited between April 2000 and August 2015. 
The study was approved by the ethics committee of North-western and Central Switzerland 
(EKNZ) and was conducted in accordance with the Declaration of Helsinki. All participants 
provided written informed consent. 
 
2.2 Screening Procedure 
ARMS patients were identified using the Basel Screening Instrument for Psychosis (BSIP), 
which was developed by Riecher-Rössler et al. (2008). The BSIP allows the rating of 
individuals regarding the inclusion/exclusion criteria corresponding to the Personal 
Assessment and Crisis Evaluation (PACE) criteria by Yung et al. (1998) and has been shown 
to have a high predictive validity (Riecher-Rössler et al., 2008; Riecher-Rössler et al., 2009).  
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Exclusion criteria were age <18, insufficient knowledge of German, IQ <70, previous 
episode of schizophrenic psychosis (treated with antipsychotics for >3 weeks (lifetime) and/or 
a total amount of ≥ 2500mg chlorpromazine equivalent), psychosis clearly due to organic 
reasons or substance abuse, or psychotic symptoms within a clearly diagnosed affective 
psychosis or borderline personality disorder (Riecher-Rössler et al., 2007).  
 
2.3 Psychopathological Assessments 
Negative symptoms were assessed with the Scale for the Assessment of Negative 
Symptoms (SANS; Andreasen, 1989). Variables used in statistical analyses were the SANS 
total score and its five original subscales (i.e., affective flattening, alogia, avolition/apathy, 
asociality/anhedonia and inattention). Positive psychotic symptoms were assessed using the 
Brief Psychiatric Rating Scale (BPRS; Ventura et al., 1993). For statistical analyses we used 
the factor psychosis of the BPRS four-factor structure proposed by Velligan et al. (2005).  
 
2.4 Neurocognitive Assessment 
We used a neuropsychological test battery which was mainly based on computer-
administered tests. The domains and tests included were as follows: General intelligence 
was assessed using the Mehrfachwahl-Wortschatz-Test (MWT-A; Lehrl, 1991) and the 
Leistungsprüfungssystem, scale 3 (LPS; Horn, 1983). Both tests are well-established 
German intelligence scales for estimating verbal (MWT-A) and non-verbal (LPS) abilities 
(i.e., abstract reasoning). Planning ability was evaluated with the Tower of Hanoi (ToH; 
Gediga and Schöttke, 1994), cognitive flexibility with the Wisconsin Card Sorting Test 
(WCST; Drühe-Wienholt and Wienholt, 1998), selective attention and reaction inhibition with 
the Go/No-Go subtest of the Test of Attentional Performance (TAP; Zimmermann and Fimm, 
1993). Working memory was measured with the TAP working memory (WM) subtest 
(Zimmermann and Fimm, 1993), verbal learning and memory with the California Verbal 
Learning Test (CVLT; Delis et al., 1987) and verbal fluency with the Verbal Fluency Test 
(VF), which is based on the German Regensburger Wortflüssigkeits-Test (RWT; 
Aschenbrenner et al., 2000). Since the latter was only introduced into the FePsy study 
design in 2013, it was only obtained in a small subset of the included ARMS patients. 
Attention was assessed with the Continuous Performance Test (CPT-OX; Rosvold et al., 
1956), which in a stricter sense measures vigilance. For a more detailed description of the 
above mentioned tests, see Rapp et al. (2013) or Pflueger et al. (2007).  
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2.5 Statistical Analyses 
All statistical analyses were conducted using the IBM Statistical Package for the Social 
Sciences Version 22.0 (IBM Corp., 2013) and the R environment for statistical computing (R 
Core Team, 2016).  
 We applied various transformations to variables of the SANS, the BPRS and the 
neuropsychological test battery that did not conform to assumptions of normality (see 
Supplementary Table 1). Additionally, some neuropsychological variables were recoded, 
such that a higher score always indicated a better performance. To reduce statistical 
analyses, composite scores were calculated for each subtest of the neuropsychological test 
battery in accordance with other studies (Lewandowski et al., 2011; Rapp et al., 2013). All 
composite scores were the average of the z-transformed performance scores and were only 
included in further analyses, if their internal consistency reached a minimum Cronbach’s α of 
.7, as suggested in Field (2013). Following this guideline, composite scores were obtained 
for ToH (α = .88), WCST (α = .86), CVLT (α = .76) and VF (α = .78). Measures of overall 
reliability for TAP Go/No-Go (α = .34), TAP-WM (α = .50), CPT (α = .20), and IQ (α = .46) did 
not reach satisfying levels. Therefore, composite scores of TAP Go/No-Go, TAP-WM and 
CPT were replaced with the measure of sensitivity called d prime (d’; d’-TAP Go/No-Go, d’-
TAP WM and d’-CPT), which takes both hits and false alarms into account by calculating the 
relative proportion of those components in a task (Haatveit et al., 2010). To generate normal 
distribution, some d’ variables were subsequently transformed (see Supplementary Table 1). 
For IQ, the single variables of verbal (MWT-A IQ) and non-verbal (LPS IQ) intelligence were 
used for further statistical analyses instead of the composite score. 
 Multiple linear regression models were fitted to explore the relationship between 
negative symptoms and neurocognition. Cognitive variables such as composite scores, d’ 
variables and the two IQ measures served as independent variables, the SANS total score 
and the BPRS psychosis factor were entered as dependent variables. Separate linear 
regression models were fitted for each cognitive composite score and dependent variable. 
The different subscales of negative symptoms were only further analyzed if a significant 
result emerged regarding the SANS total score. Age and gender were included as covariates 
in all models. Testing was two-tailed at a 5% significance level and missing values were 
excluded listwise. To account for multiple testing, corrected p-values were calculated 
separately for the SANS total score and for each negative symptom subscale using the false 
discovery rate (Benjamini and Hochberg, 1995).  
 
3. Results 
In total, data of 154 ARMS patients who met the requested inclusion criteria were analyzed. 
11 patients did take antipsychotic medication, which however did not exceed a total 
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cumulative lifetime dose of 2500 mg of chlorpromazine equivalents. Sociodemographic and 
clinical sample characteristics are presented in Table 1.  
 
 
 
- Insert Table 1 about here - 
 
3.1 Regression analyses 
Detailed information of multiple linear regression analyses for SANS total score can be found 
in Table 2. After correction for multiple testing, regression analyses revealed significant 
negative associations between SANS total score and verbal fluency as well as with non-
verbal IQ, whereby verbal fluency showed the strongest negative association. Multiple 
regression models including the BPRS psychosis factor as dependent variable revealed that 
no cognitive variable was significantly associated with positive psychotic symptoms of the 
BPRS.  
 
- Insert Table 2 about here - 
 
The following results emerged when the SANS subscales were further analysed:   
- Alogia was significantly associated with both nonverbal IQ (p = .024) and verbal 
fluency (p = .024).  
- Asociality/Anhedonia was significantly associated with nonverbal IQ (p = .023).  
The subscales Affective Flattening, Avolition/Apathy and Inattention did not withstand 
correction for multiple testing. Information on the associations between neurocognitive 
domains and psychopathological symptoms corrected for multiple testing is summarized in 
the heat map (see Figure 1).  
 
- Insert Figure 1 about here - 
 
 
4. Discussion 
 
The aim of this study was to investigate the relationship between negative symptoms and 
cognitive functioning in a sample of 154 ARMS patients, analyzing each negative symptom 
domain separately. In accordance with our hypothesis, we found that patients suffering from 
more severe negative symptoms performed worse in most neurocognitive tasks, while frank 
positive psychotic symptoms were not significantly associated with cognitive performance. 
These results are consistent with most previous studies investigating the associations 
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between psychopathological symptoms and cognitive functioning in ARMS (Gur et al., 2015; 
Lindgren et al., 2010; Meyer et al., 2014) and FEP patients (de Gracia Dominguez et al., 
2009). However, not all performed studies have found associations between negative 
symptoms and cognitive deficits among ARMS patients (Kim et al., 2011; Niendam et al., 
2006; Ohmuro et al., 2015; Pukrop et al., 2007). This might be due to the rather small sample 
sizes in those studies. In addition, Niendam et al. (2006) made use of the conservative 
Bonferroni correction. However, the associations observed by Niendam et al. (2006) and 
Ohmuro et al. (2015) showed the same pattern as in studies reporting significant 
associations. 
 When we corrected our analyses for multiple testing, the strongest association was 
found between negative symptoms and verbal fluency, with a higher SANS total score 
associated with reduced verbal fluency. This result is in line with our hypothesis and matches 
the results reported in FEP patients (de Gracia Dominguez et al., 2009). Verbal fluency 
seems to be impaired already in the early stages of emerging psychosis and has previously 
been suggested as a possible predictor for transition to psychosis (Addington et al., 2017; 
Becker et al., 2010; Hauser et al., 2017). Furthermore, studies have indicated that ARMS 
and FEP patients show reduced activation in the anterior cingulate gyrus (Fu et al., 2005; 
Fusar-Poli et al., 2011; Schaufelberger et al., 2005), the inferior frontal cortex and the inferior 
prefrontal cortex (Fu et al., 2005; Schaufelberger et al., 2005) when performing verbal 
fluency tasks. As other studies in ARMS (Fornito et al., 2008) and patients with schizophrenic 
psychoses (Bersani et al., 2014) have shown, cingulate regions seem not only to be linked to 
verbal fluency, but also to negative symptoms. It might be speculated that this association 
points to similar pathogenic pathways of negative symptoms and verbal fluency deficits.   
 Alternatively, the association found between verbal fluency and negative symptoms 
may be indicative of an overlap between these constructs. When the SANS negative 
symptom subscales were investigated separately, verbal fluency was only found to be 
associated with the alogia subscale. Thus, it could be suspected that an impaired verbal 
fluency leads to the clinical impression of alogia. Vice versa, it seems logical that patients 
suffering from alogia show lower cognitive performance in tasks involving verbal fluency. 
Thus it might be possible that some of the associations found in this study might be 
explained by a construct overlap.  
We used the SANS for the assessment of negative symptoms, an instrument that has 
previously been criticized for the inclusion of inattentiveness, which per se measures 
cognition rather than negative symptoms (Lincoln et al., 2016), and represents a further area 
of construct overlap. Recent studies have pointed out that the conceptualization of negative 
symptoms has changed over the years (Blanchard et al., 2011) and efforts have been made 
to develop new assessment instruments such as the Clinical Assessment Interview for 
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Negative Symptoms (CAINS; Kring et al., 2013) and the Brief Negative Symptom Scale 
(BNSS; Kirkpatrick et al., 2011), which are both based on this new conceptualization (see 
Carpenter et al., 2016; Lincoln et al., 2016 for review). Thus, future studies should use these 
novel scales when assessing negative symptoms, as they allow for a clearer distinction 
between negative symptoms and cognition. 
 After correction for multiple testing also the association between negative symptoms 
and nonverbal intelligence remained significant, with increasing negative symptoms being 
associated with lower nonverbal IQ. Here, nonverbal intelligence was significantly associated 
with 2 out of 5 negative symptom subscales (i.e., alogia and asociality/anhedonia). Earlier 
studies have reported significant associations between full-scale IQ and negative symptoms 
in patients with affective and non-affective psychoses (de Gracia Dominguez et al., 2009; 
Kravariti et al., 2012) and in patients with schizophrenic psychoses (Basso et al., 1998). 
However, studies explicitly analyzing associations of nonverbal intelligence with negative 
symptom subscales are lacking so far. Also, such studies have not yet been published for 
ARMS patients. Thus, to the best of our knowledge, this is the first study to analyze this 
specific relationship in ARMS patients, indicating that nonverbal intelligence is more strongly 
associated with negative symptoms than verbal intelligence.  
 Some points need to be discussed regarding the direction of the association between 
negative symptoms and neurocognition. As data were analyzed cross-sectionally, the 
present findings do not implicate causality. Studies which longitudinally investigated the 
predictive relationship of cognitive functioning and negative symptoms in FEP patients and 
individuals with schizophrenic psychoses found inconsistent results. For example, Lipkovich 
et al. (2009) found that processing speed affected psychosocial functioning directly and 
indirectly via negative symptoms at a 6-week follow-up. Schüpbach et al. (2007) reported 
that an early improvement of negative symptoms predicted better neurocognitive 
performance at a 2-year follow-up. Nevertheless, the authors also found that an early 
improvement of cognitive deficits was significantly associated with an improvement of both 
negative and positive symptoms at 2-year follow-up (Schüpbach et al., 2007). Given that 
cognitive deficits share a neurodevelopmental as well as a genetic component (Bora et al., 
2014; Kim et al., 2011), it might be assumed that cognitive deficits develop long before 
negative symptoms arise. Therefore, cognitive deficits may predict the severity of negative 
symptoms in ARMS patients rather than the other way round.  
When interpreting results associated with cognition, motivational aspects should also 
be taken into account. An individual’s motivation may have a major impact on 
neuropsychological testing and results. In a recent study Moritz et al. (2017) performed 
mediation analyses and found that motivational deficits contributed to poorer neurocognitive 
performance.  
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4.1 Strenghts and Limitations   
Results obtained in this study are based on cross-sectional data only. Further analyses 
should focus on longitudinal data to investigate the predictive relationship between 
neurocognition and negative symptoms.  
 Strenghts of our study were that we used a comparably larger sample of ARMS 
patients than the majority of the previous studies did, which improved the statistical power of 
our study. Also, we analyzed every negative symptom subscale separately to investigate the 
relationship of negative symptoms and cognition in a more detailed way. All results were 
controlled for the covariates age and gender. Only 11 out of 154 patients were treated with 
antipsychotic medication and results did not differ when analyses were performed with and 
without controlling for intake of antipsychotic medication.  
 
4.2 Conclusions 
Taken together, our results suggest that worse neurocognitive performance is associated 
with a higher level of negative symptoms in ARMS patients. Measures of nonverbal 
intelligence and verbal fluency were particularly associated with negative symptoms in this 
study. The strong association found between verbal fluency and negative symptoms may be 
indicative of an overlap between those constructs, since impaired verbal fluency might lead 
to the clinical impression of alogia.  
Future studies should focus on a better differentiation between cognitive deficits and 
negative symptoms to reduce construct overlap. Furthermore, a multimodal approach 
incorporating neuroimaging in addition to psychopathological and neuropsychological data 
could provide further insights into the underlying pathogenic processes of cognitive deficits 
and negative symptoms. Detecting and treating these processes as early as possible in 
ARMS patients would assure the best possible functional outcome. 
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Table 1 
Sociodemographic and clinical characteristics of included ARMS patients. 
                                          
                                                        ARMS total group (n = 154) 
   n     %      M  SD 
Men 104 67.5%   
Women   50 32.5%   
Age     25.94 7.38 
Years of education     11.62 2.88 
Antipsychotics1 currently 
     None 
     Risperidone 
     Quetiapine 
     Olanzapine 
 
142 
    4 
    1 
    6 
 
92.9% 
  2.6% 
  0.6% 
  3.9% 
  
 
 
 
 
Antidepressants currently   51 33.1%   
Anxiolytics currently   27 17.5%   
SANS total score   21.44 17.62 
BPRS psychosis     6.17   2.59 
Note. ARMS: At-risk mental state; SANS: Scale for the Assessment of Negative Symptoms; BPRS: 
Brief Psychiatric Rating Scale.  
1
Antipsychotics: only patients with a cumulative lifetime exposure of less than a total chlorpromazine 
equivalent of 2500 mg were included.  
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Table 2 
Associations between the SANS total score and performance in various neurocognitive domains. 
 
SANS Total score 
Predictor n β T B SE CI p - value p – value (corrected) 
Verbal IQ 94 -.19 -1.74 -.22 .13 -.47 to .03 .085 .102 
Non-Verbal IQ 93 -.32 -3.15 .00 .00 -.003 to -.001 .002** .020* 
Planning Ability 81 -.22 -2.01 -5.09 2.53 -10.12 to -.05 .048* .072 
Cognitive Flexibility 90 -.18 -1.71 -3.83 2.24 -8.29 to .63 .091 .102 
Verbal Fluency 27 -.51 -2.86 -10.94 3.82 -18.84 to -3.04 .009** .040* 
Verbal Learning & Memory 79 -.27 -2.30 -7.30 3.17 -13.61 to -.99 .024* .051 
Selective Attention &  Inhibition 92 -.23 -2.23 -6.23 2.80 -11.79 to -.68 .028* .051 
Working Memory 93 -.25 -2.42 -4.85 2.00 -8.83 to -.87 .017* .051 
Vigilance 86 .00 .02 .00 .05 -.10 to .10 .986 .986 
Note. SANS: Scale for the Assessment of Negative Symptoms; Verbal IQ: Mehrfachwahl-Wortschatz-Test (MWT-A); Non-Verbal IQ: Leistungsprüfungssystem (LPS); Planning 
Ability: Tower of Hanoi (ToH); Cognitive Flexibility: Wisconsin Card Sorting Test (WCST); Verbal Fluency: Verbal Fluency Test (VF); Verbal Learning and Memory: California Verbal 
Learning Test (CVLT); Selective Attention and Reaction Inhibition: d’ of the Test of Attentional Performance, Go/No-Go subtest (TAP Go/No-Go); Working Memory: d’ of the Test of 
Attentional Performance, Working Memory subtest (TAP-WM); Vigilance: d’ of the Continuous Performance Test (CPT).  
β: standardized regression coefficient; B: unstandardized regression coefficient; SE: standard error; CI: 95% confidence interval; Each of the multiple regressions was performed 
with one neurocognitive predictor. The covariables age and gender are not listed. 
* p   < .05 
** p < .01 
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Figure 1. Associations between psychopathology subscales and neurocognitive domains. 
Note. SANS: Scale for the Assessment of Negative Symptoms; BPRS: Brief Psychiatric Rating Scale.  
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